CompanyGraph
Roquefort Therapeutics plc
ROQ · United Kingdom
roquefortplc.comFinancials as of FY2024 · latest on file
At a glance
- Depends onUpstream position: supplies 6 industries, depends on 3
- ScaleMarket cap is $2.1M, lower than 95% of all stocks globally
- Interpretations4 currently firing — 4
Sign in to view price data.
Sign inThe reported statements, read against the company's own industry.
As of FY2024 (year ended December 31, 2024). Newer annual figures aren't yet on file.
Financials view
Market Capitalization
1.56MGBP2.10M · vs all stocks (USD)
Revenue (TTM)
0.00GBPvs all stocks (USD)
Profit Margin
0.00%vs Biotechnology peers
Beta
-0.5590xvs all stocks
52-Week Change
-42.42%vs all stocks
Market Capitalization
1.56MGBP2.10M · vs all stocks (USD)
Enterprise Value
1.70MGBP2.29M · vs all stocks (USD)
Price to Book (MRQ)
0.0315xvs Biotechnology peers
Enterprise to EBITDA
-1.83xvs Biotechnology peers
Profit Margin
0.00%vs Biotechnology peers
Operating Margin
0.00%vs Biotechnology peers
Return on Assets (TTM)
-9.93%vs Biotechnology peers
Return on Equity (TTM)
-18.23%vs Biotechnology peers
Revenue (TTM)
0.00GBPvs all stocks (USD)
Revenue per Share (TTM)
0.00GBPUpdated Aug 8, 2026Gross Profit (TTM)
0.00GBPvs all stocks (USD)
EBITDA (TTM)
-926.73KGBP-1.25M · vs all stocks (USD)
Net Income (TTM)
-882.45KGBP-1.19M · vs all stocks (USD)
Operating Cash Flow (TTM)
-588.75KGBP-795.13K · vs all stocks (USD)
Levered Free Cash Flow (TTM)
-2.18MGBP-2.94M · vs all stocks (USD)
Trailing Annual Dividend Rate
0.00GBPUpdated Aug 8, 2026Trailing Annual Dividend Yield
0.00%vs all stocks
Payout Ratio
0.00%vs Biotechnology peers
Revenue
0.00GBPFY2024 · Dec 31, 2024Cost of Goods Sold
16.00KGBPFY2024 · Dec 31, 2024Gross Profit
-16.00KGBPFY2024 · Dec 31, 2024Operating Income
-1.12MGBP-1.51M · vs all stocks (USD)
Pre-tax Income
-1.21MGBPFY2024 · Dec 31, 2024Income Tax Expense
-242.77KGBPFY2024 · Dec 31, 2024Net Income
-971.80KGBPFY2024 · Dec 31, 2024EBIT
-1.17MGBPFY2024 · Dec 31, 2024EBITDA (Income Statement)
-1.16MGBPFY2024 · Dec 31, 2024Research & Development
152.91KGBPFY2024 · Dec 31, 2024Selling, General & Administrative
541.29KGBPFY2024 · Dec 31, 2024Non-operating Interest Income
0.00GBPFY2024 · Dec 31, 2024Non-operating Interest Expense
44.86KGBPFY2024 · Dec 31, 2024EPS (Basic)
-0.0750GBPFY2024 · Dec 31, 2024EPS (Diluted)
-0.0750GBPFY2024 · Dec 31, 2024Basic Shares Outstanding
13.00MSharesFY2024 · Dec 31, 2024Diluted Shares Outstanding
13.00MSharesFY2024 · Dec 31, 2024Preferred Stock Dividends
0.00GBPFY2024 · Dec 31, 2024Operating Cash Flow
-965.31KGBPFY2024 · Dec 31, 2024Free Cash Flow
-965.31KGBPFY2024 · Dec 31, 2024Cash & Cash Equivalents (End of Period)
337.11KGBPFY2024 · Dec 31, 2024Starting Profit (CF Statement)
-1.21MGBPFY2024 · Dec 31, 2024Stock-based Compensation
21.46KGBPFY2024 · Dec 31, 2024Other Non-cash Items
97.38KGBPFY2024 · Dec 31, 2024Change in Accounts Receivable (CF)
130.41KGBPFY2024 · Dec 31, 2024Capital Expenditures
0.00GBPFY2024 · Dec 31, 2024Net Investing Cash Flow
0.00GBPFY2024 · Dec 31, 2024Long-term Debt Issuance
584.91KGBPFY2024 · Dec 31, 2024Net Financing Cash Flow
584.91KGBPFY2024 · Dec 31, 2024Shares Outstanding
16.37MSharesUpdated Aug 8, 2026Float Shares
11.38MSharesUpdated Aug 8, 2026% Held by Insiders
1.55%vs all stocks
% Held by Institutions
0.05%vs all stocks
Total Cash (MRQ)
182.92KGBP247.04K · vs all stocks (USD)
Total Cash per Share (MRQ)
0.0120GBPUpdated Aug 8, 2026Total Debt (MRQ)
383.65KGBP518.13K · vs all stocks (USD)
Total Debt to Equity (MRQ)
0.0807xvs Biotechnology peers
Current Ratio (MRQ)
2.80xvs Biotechnology peers
Book Value per Share (MRQ)
0.3020GBPUpdated Aug 8, 2026Total Assets
5.75MGBP7.77M · vs all stocks (USD)
Total Current Assets
362.49KGBPFY2024 · Dec 31, 2024Total Liabilities
861.73KGBPFY2024 · Dec 31, 2024Total Non-current Assets
5.39MGBPFY2024 · Dec 31, 2024Total Non-current Liabilities
281.91KGBPFY2024 · Dec 31, 2024Total Current Liabilities
579.82KGBPFY2024 · Dec 31, 2024Cash
337.11KGBPFY2024 · Dec 31, 2024Cash & Cash Equivalents
337.11KGBPFY2024 · Dec 31, 2024Accounts Payable
23.03KGBPFY2024 · Dec 31, 2024Short-term Debt
400.09KGBPFY2024 · Dec 31, 2024Common Stock (Book)
1.36MGBPFY2024 · Dec 31, 2024Retained Earnings
-5.27MGBPFY2024 · Dec 31, 2024Total Shareholders' Equity
4.89MGBP6.60M · vs all stocks (USD)
52-Week Low
0.9500GBXUpdated Aug 8, 202652-Week High
30.00GBXUpdated Aug 8, 202652-Week Change
-42.42%vs all stocks
Beta
-0.5590xvs all stocks
50-Day MA
10.11GBXUpdated Aug 8, 2026200-Day MA
14.79GBXUpdated Aug 8, 2026Avg 10-Day Volume
712.69KSharesUpdated Aug 8, 2026Avg 30-Day Volume
326.38KSharesUpdated Aug 8, 2026Diluted EPS (TTM)
-0.0100GBPUpdated Aug 8, 20264 interpretations currently present — each is a set of fired observations whose alignment reads as one structural pattern. Click an observation to see the numbers behind it.
Screen for these patternsIs this company financially stable?
Diagnostic
Goodwill-Heavy Equity
Equity looks heavy for the industry, but much of it is goodwill from past acquisitions.
Reads
Intangible Concentration
Much of what it owns is goodwill from past deals, large next to its equity.
Reads
Where is this company structurally exposed?
Decline With Range Expansion And Drawdown
The price is falling, swinging wider than usual, and sits well below its peak.
Ulcer Index Elevated, Drawdown From Peak Significant, 20-Week Volatility Elevated
It sits well below its peak, and the fall has been both deep and long.
An interpretation is present only while every observation it reads stays fired (score ≥ 70). It describes what the aligned readings show — never a verdict, never a prediction.
Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Supply Chain
Upstream position: supplies 6 industries, depends on 3Notable
Outgoing: 6.00Incoming: 3.00
Scale
Market cap is $2.1M, lower than 95% of all stocks globallySignificant
Market cap (USD): 2,100,614.024Global P5: 269,387,740.27
Revenue is $0, lower than 95% of all stocks globallySignificant
Revenue (USD): 0.00Global P5: 30,274,777.221
Companies that share the same coordination system — how they create, deliver, or capture value.
Futura Medical plc
Tier 1ProductionApproval-Gated PipelineRule
Nuformix Plc
Tier 1ProductionApproval-Gated PipelineRuleSenseMaking
TheracryF PLC
Tier 1ProductionApproval-Gated PipelineRule
Purple Biotech Ltd.
Tier 1ProductionApproval-Gated PipelineRuleRisk
XTL Biopharmaceuticals Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Sulzer Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Thalia Therapeutics Plc
Tier 1ProductionApproval-Gated PipelineRule
Sailong Pharmaceutical Group Inc.
Tier 1ProductionApproval-Gated PipelineRule
Crism Therapeutics Corporation
Tier 1ProductionApproval-Gated PipelineRuleRisk
Cizzle Biotechnology Holdings Plc
Tier 1ProductionApproval-Gated PipelineRule
Companies that share active interpretations — structural patterns currently present in both stocks.
The Smarter Web Company Plc
4 interpretationsGoodwill-Heavy EquityIntangible ConcentrationDecline With Range Expansion And DrawdownUlcer Index Elevated, Drawdown From Peak Significant, 20-Week Volatility Elevated
Bakkt Holdings, Inc.
3 interpretationsGoodwill-Heavy EquityDecline With Range Expansion And DrawdownUlcer Index Elevated, Drawdown From Peak Significant, 20-Week Volatility Elevated
Energypathways Plc
3 interpretationsGoodwill-Heavy EquityIntangible ConcentrationUlcer Index Elevated, Drawdown From Peak Significant, 20-Week Volatility Elevated